OR WAIT null SECS
Connor Iapoce is an assistant editor for HCPLive and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at email@example.com.
Schuyler Jones, MD discusses risk stratification in CAD/PAD and treatments aimed at atherothrombosis.
In an interview with HCPLive®, Schuyler Jones, MD, Duke University School of Medicine, recapped his recent discussion on identification of patients with CAD/PAD and risk stratification of those patients.
Jones recently took part in an HCPLive® State of the Science "Institutional Perspectives in Cardiology: Cardiovascular Risk Management" event, chaired by Manesh Patel, MD, Duke University School of Medicine.
His presentation was titled "CAD/PAD: Identifying Risk & Summary of Recent Clinical Trials."
"We really focused primarily on the identification of high risk patients with symptomatic PAD and symptomatic CAD and then treatments that really were aimed primarily at atherothrombosis," Jones said. "So low dose rivaroxaban, as well as high intensity statins and PCSK9 inhibitors."
He noted research topics on improving cardiovascular outcomes he is interested in pursuing further.
"Especially for my topic, the opportunity to study any high risk patient for things like cardiovascular events who are also high risk for bleeding," Jones said. "The opportunity is great to continue to improve ischemic outcomes while minimizing bleeding outcomes."